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The effect of treating bacterial vaginosis on preterm labor
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Objective: Multiple studies suggest that bacterial vaginosis (BV) causes preterm labor; yet its routine treatment
remains controversial. In order to help to elucidate this controversy, we performed a thorough review of studies
with levels of evidence ranging from I to II–II.
Methods: We searched for all of the studies from the years 1994 to 2001 via Medline’s database, including
MD Consult and Ovid Mednet.
Results: Several trials discovered a decrease in the incidence of preterm labor when BV was treated, but most
of those trials were performed on women with a history of preterm labor. However, the majority of trials
reviewed advise against treatment of a general low-risk obstetric population, as there was no significant decrease
in preterm labor.
Conclusions: Therefore, based on the above studies and the current guidelines of the Centers for Disease
Control and Prevention (CDC), treating pregnant women in high-risk populations who are diagnosed with BV
provides the clinician with an opportunity to possibly prevent preterm labor in this population. In nulliparous
women without a history of preterm birth, treatment is recommended if other risk factors are present (e.g.
gonorrhea or chlamydia). However, in the general low-risk populations, routine screening is not indicated.
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Premature births remain a serious problem in
the USA, occurring in 11% of all pregnancies.
Preterm birth, defined as delivery of an infant
before 37 weeks’ gestation, is also the leading
cause of neonatal mortality and morbidity in the
developed world. In the USA alone, an excess of
$4 billion1, or 57% of direct nursery costs2 can be
attributed to the care of premature infants. In
addition, infants who survive exhibit an increased
risk of long-term morbidity, chronic lung disease,
cerebralpalsy,developmentaldelay,andvisualand
hearing impairment1,2.
Causes of preterm labor vary, but infection is
highlysuspect.Upto80%ofearlyprematurebirths
are associated with an intrauterine infection prior
to the rupture of membranes. Asymptomatic
bacteriuria, Neisseria gonorrhea, Chlamydia tracho-
matis, Trichomonas vaginalis and bacterial vaginosis
(BV)haveallbeenassociatedwithanincreasedrisk
of preterm birth3. The exception is vaginal yeast
infections4. Risk factors for preterm delivery are
listed in Table 1. Multiple studies suggest that
BV is a cause of preterm labor, yet its routine
treatment remains controversial5–8.
In conjunction with preterm delivery, BV in
pregnant patients is associated with premature
rupture of membranes, infection of the amnion
and chorion, histologic chorioamnionitis and
infection of amniotic fluid. Flynn et al.5 noted a
60% increase in the risk of preterm delivery in the
presence of BV. Another study by Hillier et al.6
associated BV with risk of spontaneous preterm
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 2003 The Parthenon Publishing Group 123birth by a factor of 1.5 to 3 in high-risk women,
while other studies suggest that BV almost doubles
the risk of spontaneous preterm delivery7.
Although BV is present in almost 20% of preg-
nant women, most cases remain asymptomatic,
and not all women with the condition will deliver
prematurely8.Itispostulatedthatthereexistsasub-
group of high-risk women (e.g. those who have
vaginal colonization with Mycoplasma hominis).
African–American women may also exhibit
200–300% more BV than white populations7,8.
The exact conditions under which BV directly
correlates with preterm labor are unknown5.
The purpose of this paper is to review the
recent literature addressing the association
between BV and preterm birth4.
METHODS
In order to perform this review, we searched the
Medline database, including MD Consult and
Ovid Mednet for the years 1994–2001. Some of
thesearchtermsincludedpretermlabor,BV,treat-
ment, metronidazole, clindamycin, and vaginitis.
RESULTS
Hauth et al. (Level I study in 1995) treated
pregnant women with a history of preterm birth
or weight < 50 kg and a positive diagnosis of BV7.
Treatment consisted of metronidazole (250 mg
three times a day for 7 days) and erythromycin
(333 mg three times a day for 14 days). The results
of this 2:1double-blind randomization trial
revealed a decreased incidence of preterm delivery
(< 37 weeks) for the entire study population (odds
ratio, OR, 0.48; 95% confidence interval, CI
0.28–0.81), as well as for a subset of patients with a
previous preterm delivery (OR, 0.48; 95% CI,
0.25–0.90).WomenwhowerediagnosedwithBV
at the initial visit (24 weeks) and who received
antibiotics rather than placebo presented with
fewer preterm deliveries. Since this treatment
benefit was only observed at initial examination,
the overall results do not support mid-trimester
treatment with metronidazole and erythromycin
in women at risk for preterm delivery without
BV. There are no data to suggest that treatment
of low-risk pregnant women with BV decreases
the rates of prematurity7.
Over a period of 3 years, Morales et al. (level I
studyin1994)screenedforBVinwomenbetween
13 and 20 weeks with a singleton gestation and
a history of preterm birth via a double-blind
randomized trial. The 80 women with a positive
screen received either metronidazole (250 mg
threetimesaday)oraplacebofor7days.Thestudy
showed a significant decrease in delivery prior
to 37 weeks among women taking metronidazole
(18%) compared with those on placebo (39%)
(p < 0.05). In the metronidazole group there were
significantly fewer hospital admissions for preterm
labor, cases of premature rupture of membranes,
and low birth weights9.
In 1995, McGregor et al. (level I study)
performedaprospective,controlledtreatmenttrial
of 1260 subjects to study the effect of clinda-
mycin on pregnant women with BV. Women
who were treated with 300 mg of clindamycin
orally twice daily for 7 days showed a reduction in
preterm birth (relative risk 0.5; 95% CI, 0.3–0.9),
and the authors recommended that women at risk
for preterm birth with BV should be screened and
treated1.
In 1997, McDonald et al.10 conducted a
multicenter, randomized, placebo-controlled trial
of 879 women at 19 weeks’ gestation, but failed
to demonstrate a reduced preterm birth rate
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History of preterm birth
Multiple gestation
Bacterial vaginosis
Urinary tract infection
Crack cocaine usage
Abruption
Second- and third-trimester vaginal bleeding
Maternal age under 16 years or over 40 years
African–American race
History of uterine surgery
Smoking
Strenuous work
Polyhydramnios and oligohydramnios
Cervical infections
Cervical incompetence
Pre-eclampsia
Premature preterm rupture of membranes
Domestic violence
Retained intrauterine device
Table 1 Risk factors for preterm labor
1,2among pregnant women with BV or those with a
heavy growth of Gardnerella vaginalis (level I). The
intention-to-treat analysis showed no difference
between the treatment and placebo groups in
overall preterm birth (31/429 [7.2%] vs. 32/428
[7.5%]) or spontaneous preterm birth rate (20/429
[4.7%] vs. 24/428 [5.6%]). However, among
women with a previous preterm birth, those
treated with oral metronidazole (400 mg twice
daily for 2 days at 24 weeks’ gestation, and again at
29 weeks) demonstrated a marked reduction in
spontaneous preterm birth rate (OR, 0.14; 95%
CI, 0.01–0.84)10.
A meta-analysis from the Cochrane database
determined that preterm birth rates did not differ
significantly between treated and non-treated
pregnant patients with BV (OR, 0.78; 95%
CI, 0.60–1.02), yet a subgroup of women with a
previous preterm birth demonstrated a significant
decrease in the incidence of preterm birth, with an
odds ratio of 0.37 (95% CI, 0.23–0.60)3. This
meta-analysis of 1504 women from a total of five
trials using amoxicillin, clindamycin and metro-
nidazole did not recommend screening and treat-
ing all pregnant women for BV in order to
prevent preterm birth.
Carey et al.11 recently conducted a randomized,
double-blind clinical trial of the use of metro-
nidazole to treat asymptomatic BV. Treatment
did not reduce the frequency of delivery before
37 weeks’ gestation (relative risk in the metro-
nidazole group, 1.0; 95% CI, 0.8–1.2). This
clinical trial differed from previous attempts
because it was larger (1953 subjects) and it studied
the general obstetrical population, not just women
with a history of preterm delivery. Treatment
involvedashortercourseofmetronidazoletherapy
with two 2 g doses during a 48-hour period, and
a second treatment of the women between 24
and 30 weeks’ gestation. These researchers
recommended the longer course of therapy to
eradicate upper genital tract organisms11.
The results of this study supported those of
McDonald et al.10 in that metronidazole did not
reduce preterm delivery among the general
population of pregnant women, nor did it reduce
hospital admissions for preterm labor or preterm
premature rupture of the membranes, postpartum
endometritis, clinical intra-amniotic infections,
vaginal infections serious enough to require treat-
ment, and treatment with tocolytic drugs. The
placebo and metronidazole groups did not differ
with regard to incidence of admissions to the neo-
natal intensive-care unit, passage of meconium, or
fetal death/neonatal death. This study found
that routine screening of pregnant women for
asymptomatic BV and treating the latter with a
short course of orally administered metronidazole
did not reduce the risk of preterm birth, despite its
effectiveness in eradicating BV. Studies do not
support the use of metronidazole treatment in
pregnant women with asymptomatic BV who are
considered to be at either high or low risk for
preterm delivery11. Studies by McDonald et al.10,
Morales et al.9 and Hauth et al.7 did find evidence
of a decreased incidence of recurrent pre-
term delivery among women with a prior
preterm delivery treated with metronidazole or
metronidazole/erythromycin.
ThefindingsofJoesoefetal.12concurwiththose
of Carey et al.11. This multicenter, double-blind,
randomized, placebo-controlled trial failed to
demonstrate a reduction in preterm delivery
(level I, 1995) in 745 women between 14 and
26 weeks’ gestation who were diagnosed with BV
(via Gram stain score > 6) with 2% clindamycin
vaginal cream or with a placebo cream for 7 days.
Although 15% of the women treated with
clindamycin had a preterm delivery, only 13.5% of
placebo patients did (OR, 1.1; 95% CI, 0.7–1.7).
Theauthorsproposedthattheincreasedfrequency
of preterm delivery might be caused by a transient
increase in vaginal colonization by Escherichi coli
andEnterococcus1monthaftertherapy.Since E.coli
is linked to an increased risk of preterm delivery,
this may explain the value of 15%, compared
with the 13.5% difference found in the study by
Joesoef et al.12.
In 1994, McGregor et al.13 evaluated 271
women between 16 and 27 weeks’ gestation in a
double-blind trial (level I). Women who were
diagnosed with BV were treated with 2%
clindamycin vaginal cream or placebo for 7 days.
Although 2% clindamycin vaginal cream was
effective in treating BV during pregnancy
(p = 0.001) it was not permanent, as the condition
gradually returned, and treatment did not reduce
theriskofprematurityduringthesecondtrimester.
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power of the study, the timing of treatment, and
the use of local vaginal treatment13.
In 2001, Kekki et al.14 performed a multicenter,
randomized, double-blind, placebo-controlled
trial (level I) which showed that the treatment of
BV in early pregnancy with vaginal clindamycin
for 7 days did not decrease the rate of preterm
deliveries or peripartum infections. In 375 ran-
domized subjects, preterm delivery occurred in
5% of the clindamycin group and 4% of the
placebo group (OR, 1.3; 95% CI, 0.5–3.5). The
efficacy of intravaginal clindamycin can be as high
as 90% in studies on non-pregnant women, and is
similar to that of oral metronidazole. The subjects
included a low-risk population of healthy women
with singleton pregnancies and without a history
of preterm delivery14. The results are similar to the
conclusion of McGregor et al.13 that topical treat-
ment in early pregnancy reduced vaginal fluid
mucinaseandsialidase,butfailedtoreducetherate
of preterm births14.
A recent randomized controlled trial by
Kurkinen-Raty et al.15 assessed the efficacy of
vaginal clindamycin in reducing preterm birth
(level I). Of the 1956 women without a history of
preterm delivery who were screened at the first
antenatal visit (gestational week 12), 143 women
tested positive for BV. After randomization and
treatment with clindamycin or placebo, the
preterm birth rate in the clindamycin group was
13.7%, compared with 6.0% in the placebo group
(OR, 2.5; 95% CI, 0.6–10). This study therefore
supports the evidence that vaginal clindamycin
treatment of BV in the first trimester does not
reduce the risk of preterm birth15.
In1999,Frenchetal.16evaluatedtheassociation
between BV, first-trimester vaginal bleeding and
preterm labor in 1100 pregnant women who were
enrolled in a prospective observational study (level
II–II).ItwasdeterminedthattreatmentofBVwith
clindamycin (300 mg orally twice daily for 7 days)
significantly reduced the risks of preterm birth
among women without first-trimester bleeding
(relative risk, 0.37; 95% CI, 0.16–0.88). Although
the overall population of women with both BV
and first-trimester vaginal bleeding experienced
reductions in preterm birth, the finding was not
statistically significant (relative risk, 0.52; 95%
CI, 0.18–1.55)16.
Several authors have proposed that the timing
of the diagnosis and/or treatment is important if
preterm labor is to be decreased. A level II–II
study by Meis et al.17 highlighted the effect of
timing of diagnosis on BV and the incidence of
preterm labor. Women who tested negative at 24
weeks but were positive when tested again at 28
weeks had the highest likelihood of preterm birth
(OR, 2.53; 95% CI, 1.32–4.85; p = 0.005)17.
Riduan et al.18 found the opposite to be true
(level II–I trial). Women who tested positive for
BV at 24 weeks and received antibiotics showed a
significantly decreased incidence of preterm birth
(OR, 0.44; 95% CI, 0.11–1.91). The authors
found that the presence of BV at 16 weeks was
more predictive of preterm delivery than its
presence at 28 to 32 weeks18.
Table 2 provides a concise summary of the
articles reviewed above.
DISCUSSION
Preterm labor may be classified as either physio-
logic or pathologic. Physiologic preterm labor
describes a normal initiating factor that occurs too
earlyinpregnancy,whilepathologicpretermlabor
results from an abnormal initiating factor with
timing being a distinguishing factor. The earlier in
pregnancy preterm labor occurs, the more likely
it is that a pathologic etiology exists. Prior
to 16 weeks’ gestation, BV is related to preterm
deliverybyariskfactorof5to7.5.After26weeks’
gestation, the risk factor drops to 1.4 to 1.919,20.
BV, an overgrowth of anaerobic species that
produce protease, phospholipase A2 and
collagenases in the vagina21, is found in 800 000
pregnant women each year11. There is disruption
of the vaginal ecosystem that results in increased
levels of anaerobes. BV alters the vaginal flora by
decreasing the number of hydrogen-peroxide-
producing Lactobacillus acidophilus organisms.
Consequently, the levels of G. vaginalis, M.
hominis, and Mobiluncus species increase rather
than remaining in their normal state of suppres-
sion. The metabolic by-products of these
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vaginal pH, and exfoliation of vaginal epithelial
cells results22.
Although the exact mechanism is not known,
studies have shown that BV can cause infection of
the upper genital tract, which acts as a premature
birth trigger6.B Va n dT. vaginalis are also asso-
ciated with many microorganisms that produce
phospholipase A2 and C or phospholipase-like
activity,andaffectedpatientsshowincreasedlevels
of sialidase, phospholipase A2, prostaglandin E2
and interleukin–1(beta). The rise in levels of
these enzymes may result in the decidual or fetal
membrane cell fatty acid tissue stores releasing
arachidonic acid2, a precursor of the uterotonic
prostaglandins.
Other explanations of an association between
BV and preterm labor include activation of
fetal and/or maternal inflammatory responses or
proteolytic enzymes. Elevated vaginal or cervical
levels of endotoxin, mucinase, sialidase and
interleukin-1(alpha)arefoundinwomenwithBV,
which suggests that the microorganisms produce
cytokines6. These cytokines and the release of
interleukin-1(beta) and tumor necrosis factor
induce cyclooxygenase II, an enzyme that pro-
duces prostaglandins involved in parturition.
Proteolytic enzymes that may overcome maternal
mucous membrane defenses and impair fetal
membrane strength and elasticity include
collagenases, immunoglobulin A proteases,
elastases, mucinases and/or sialidases2.
Several studies have concluded that screening
and treating for BV is futile, and one of the largest
clinical trials to date found no difference in the
treated low-risk pregnant population compared
with the placebo11. However, since the clinical
diagnosis of BV need not be symptomatic, screen-
ing all pregnant women who have risk factors may
be unnecessary and not cost-effective21, while
the most advantageous time to screen and the
optimum dosage of antibiotic is uncertain.
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Author Year Study type Effect on preterm labor Drug
Level of
evidence
Hauth et al.7
Morales et al.9
McGregor et al.
1
McDonald et al.10
Cochrane database3
Joesoef et al.12
Carey et al.
11
McGregor et al.
13
Kekki et al.
14
Kurkinen-Raty et al.15
French et al.
16
1995
1994
1995
1997
1991 to 2001
1995
2000
1994
2001
2000
1999
Double-blind
Placebo controlled
Prospective controlled
treatment trial
Randomized, placebo,
controlled
Meta-analysis of
controlled trials
Double-blind,
randomized, placebo
Randomized,
double-blind
Randomized,
double-blind
Double-blind, placebo
Randomized,
controlled
Prospective,
observational
Decreased in high-risk
Decreased in high-risk
Decreased in women at
high risk
Decreased only in subset
with a history of preterm
labor
No decrease in general
population, but a decrease
in those at high risk
No decrease in low-risk
population
Asymptomatic general
population without
decrease
No decrease in women at
16 to 27 weeks' gestation
No decrease in low-risk
population
No significant decrease in
low-risk population
Decreased in low-risk
population, but not
statistically significant
Metronidazole/
erythromycin
Metronidazole
Clindamycin
Metronidazole
Amoxicillin,
metronidazole
and/or clindamycin
Metronidazole
Metronidazole
(short course)
Clindamycin
Clindamycin
Clindamycin
Clindamycin
Level I
Level I
Level I
Level I
Level I
Level I
Level I
Level I
Level I
Level I
Level II–II
Table 2 Studies that have evaluated the effect of treatment of bacterial vaginosis on the incidence of preterm laborAlthoughtheTheCochraneLibrary’sreviewisan
excellent resource, our paper differs in that we
haveinvestigateddifferentaspectsofthisapproach.
We have included not only level I but also level II
studies. Furthermore, we included two studies
that investigated the effects of timing on the treat-
ment of BV17,18. However, ultimately our conclu-
sion is similar to that of the Cochrane review3.
To the clinicians who decide to screen for
and treat BV, the most effective antibiotic appears
to be oral metronidazole, which can be
safely administered during pregnancy. Vaginal
clindamycin therapy has shown slight but
statistically non-significant increases in preterm
birth rate for the reasons discussed previously23.
Analysis of the reviewed studies supports the
current guidelines of the Center for Disease
Control. Treating pregnant women in high-risk
populations who have been diagnosed with BV
can prevent preterm labor in these individuals.
In nulliparous women without a history of pre-
term birth, the recommendation is to treat if
other risk factors, such as gonorrhea or chlamydia,
are present.
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